Aptima® Herpes Simplex Viruses (HSV) 1 & 2 Test

1 in 6 Americans between the ages of 14-49 have genital herpes1

The causative factors for this, HSV-1 and HSV-2, are very prevalent. Nearly 70% of the global population is impacted by HSV-1, while prevalence for HSV-2 in the United States alone is estimated at over 24 million.1,2,3 While these viruses may be indistinguishable on initial clinical representation, they may present different health implications.

Estimated prevalence of STIs in the United States (2013)2
Not to scale

Empower your patients with a type-specific treatment plan

Each HSV type requires a unique treatment. Some cases of HSV-1 are asymptomatic.4 HSV-2 is likely to have a greater risk of transmission, and is associated with higher risk of HIV co-infection.4 Thus, treatment plans should include HIV testing and HIV reduction strategies.


Determine the appropriate treatment regimen of antiviral medication4


Providers can counsel patients according to infection type and prevent sexual and perinatal transmission4


Patients can prevent transmission to neonates and among sex partners5

NAAT tests are guideline-recommended for diagnosis of HSV infection with symptoms

WHO Recommendation5
“NAATs are increasingly preferred for HSV diagnosis due to higher sensitivity, ease of specimen collection and transportation, and faster results”
CDC Recommendation4
“A patient’s prognosis and the type of counseling needed depend on the type of genital herpes (HSV-1 or HSV-2) causing the infection. ”
ACOG Recommendation6
“Definitive diagnosis should be confirmed by a laboratory test…to determine if HSV–1 or HSV–2 is the cause of the infection.”

The Aptima HSV 1 & 2 assay:
Proven performance in sensitivity and specificity7

Sample TypeSensitivitySpecificitySensitivitySpecificity
Aptima Multitest Swab94.7%99.6%98.4%92.8%
Viral Transport Medium93.4%99.8%96.9%97.5%

Contact Us

We are here to support you. Have a question or need to talk to a Hologic team member?

1. CDC. Genital Herpes—CDC Fact Sheet. Published August 28, 2017. Accessed August 20, 2020. https://www.cdc.gov/std/herpes/stdfact-herpes.htm. 2. CDC. Incidence, prevalence, and cost of sexually transmitted infections in the United States. Published February 2013. Accessed August 20, 2020. https://www.cdc.gov/std/stats/sti-estimates-fact-sheet-feb-2013.pdf. 3. WHO. Herpes simplex virus: key facts. Published January 31, 2017. Accessed August 20, 2020. https://www.who.int/mediacentre/factsheets/fs400/en/. 4. Workowski KA, Bolan GA; CDC. Sexually transmitted diseases treatment guidelines, 2015. MMWR. 2015;64(RR-03):1-137. Updated June 5, 2015. Accessed August 26, 2020. https://www.cdc.gov/std/tg2015/tg-2015-print.pdf. 5. WHO. WHO Guidelines for the Treatment of Genital Herpes Simplex Virus. Geneva, Switzerland: WHO; 2016. 6. Lichtmacher A, Adams M, Berga S, et al. Guidelines for Women’s Health Care: A Resource Manual, Fourth Edition. Washington, DC: American College of Obstetricians and Gynecologists; 2014. 7. Aptima HSV 1 & 2 assay [package insert]. AW-15636-02. San Diego, CA: Hologic, Inc, 2017